// App-Quantinova.ai

: EXTH-09. DIANHYDROGALACTITOL (VAL-083) HAS THE POTENTIAL TO OVERCOME MAJOR CHALLENGES IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Researchers

Presenter

  • Anne Steino

Principal Investigators

  • BeiBei Zhai

  • Xiaodong Yang

  • Cassie Kline

  • Jeffrey Bacha

  • Dennis Brown

  • Mads Daugaard

  • Sabine Mueller

Medical Centers

  • Del Mar Pharmaceuticals, Vancouver, BC, Canada

  • The University of British Columbia, Vancouver, BC, Canada

  • University of California, San Francisco, San Francisco, CA

  • DelMar Pharmaceuticals, San Francisco, CA.

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dianhydrogalactitol

  • AZD-1775

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved